Safety study for aggressive NK-cell leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a new treatment approach for people with aggressive NK-cell leukemia, focusing mainly on safety. It may be offered to patients whose disease matches the study’s specific leukemia diagnosis rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of aggressive NK-cell leukemia (including if it is new or has come back).
- Your diagnosis must match the study’s agreed medical criteria based on the 2017 WHO system.
- You are not eligible to receive standard chemotherapy for your leukemia.
- If a doctor says you can use chemotherapy as your leukemia treatment, you may not qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a treatment using NK cells plus monoclonal antibodies is safe and effective for adults with relapsed or hard-to-treat acute myeloid leukemia (AML). It’s mainly looking for safety, and whether the treatment can help control the leukemia.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This study looks at natural killer (NK) cells, a type of immune cell, in patients with acute leukemia or myelodysplastic syndrome who are getting a stem cell transplant. It aims to understand how these cells change over time and may help predict outcomes.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new Aggressive NK Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.